Aikido Pharma Inc Revenue Growth Rates (DOMH), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Aikido Pharma Inc  (NASDAQ: DOMH)
    Sector • Financial    Industry • Investment Services
   Industry • Investment Services
   Sector • Financial
 

DOMH's Revenue Growth by Quarter and Year

Aikido Pharma Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/DOMH/growth
https://api.csimarket.com/api/v1/companies/DOMH/fundamentals
https://api.csimarket.com/api/v1/companies/DOMH/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
DOMH Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 16.38
2nd Quarter June 16.79
1st Quarter March 35.81
FY 68.98





DOMH Revenue third quarter 2026 Y/Y Growth Comment
Aikido Pharma Inc reported drop in Revenue in the third quarter 2026 by -68.75% to $ 16.38 millions, from the same quarter in 2025.
The fall in the third quarter 2026 Aikido Pharma Inc's Revenue compares unfavorably to the Company's average Revenue doubling of 542.98%.

Looking into third quarter 2026 results within Investment Services industry 75 other companies have achieved higher Revenue growth. While Aikido Pharma Inc' s Revenue meltdown of -68.75% ranks overall at the positon no. 3802 in the third quarter 2026.


DOMH Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -68.75 %
2nd Quarter June -56.85 %
1st Quarter March 394.61 %
FY   -

Financial Statements
Aikido Pharma Inc's third quarter 2026 Revenue $ 16.38 millions DOMH's Income Statement
Aikido Pharma Inc's third quarter 2025 Revenue $ 52.42 millions Quarterly DOMH's Income Statement


DOMH Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -2.44 %
2nd Quarter June -53.11 %
1st Quarter March 19.05 %
FY (Year on Year)   -


Back to DOMH Growth rate Comparisons >> Back to DOMH Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Investment Services Industry #76
Financial Sector #823
Overall #3802

Revenue Y/Y Growth Statistics
High Average Low
8595.77 % 542.98 % -100 %
(Sep 30 2025)   (Mar 31 2015)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Investment Services Industry #76
Financial Sector #823
Overall #3802
Revenue Y/Y Growth Statistics
High Average Low
8595.77 % 542.98 % -100 %
(Sep 30 2025)   (Mar 31 2015)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Aikido Pharma Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1256.34 % 87.8 % -100 %
(Sep 30 2023)  


DOMH's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Aikido Pharma Inc disclosed fall in Revenue from the second quarter by -2.44% to $ 16.38 millions, from $ 16.79 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Investment Services's company achievement, Most analysts pointed out.

Within Investment Services industry 71 other companies have achieved higher Revenue quarter on quarter growth. While Aikido Pharma Inc's Revenue growth quarter on quarter, overall rank is 3690.


Revenue Q/Q Growth Company Ranking
Within: No.
Investment Services Industry #72
Financial Sector #796
Overall #3690
Revenue Q/Q Growth Company Ranking
Within: No.
Investment Services Industry #72
Financial Sector #796
Overall #3690
Revenue Q/Q Growth Statistics
High Average Low
1256.34 % 87.8 % -100 %
(Sep 30 2023)  


DOMH's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Aikido Pharma Inc disclosed fall in Revenue from the second quarter by -2.44% to $ 16.38 millions, from $ 16.79 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Investment Services's company achievement, Most analysts pointed out.

Within Investment Services industry 71 other companies have achieved higher Revenue quarter on quarter growth. While Aikido Pharma Inc's Revenue growth quarter on quarter, overall rank is 3690.


Aikido Pharma Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 99.05
Y / Y Revenue Growth (TTM) -5.78 %
Year on Year Revenue Growth Overall Ranking # 44
Seqeuential Revenue Change (TTM) -26.68 %
Seq. Revenue Growth (TTM) Overall Ranking # 146


Cumulative Revenue growth Comment
For the 12 months ended Sep 30 2026 Aikido Pharma Inc reported a decrease in Revenue by -5.78% year on year, to $99 millions, compare to the 138% growth at Jun 30 2026.

Among companies within the Financial sector 5 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 31 to 44.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Investment Services Industry # 3
Financial Sector # 6
Overall # 44

Revenue TTM Y/Y Growth Statistics
High Average Low
691.09 %
 295.91 %
-68.3 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 3
Sector # 16
S&P 500 # 146
Cumulative Revenue growth Comment
For the 12 months ended Sep 30 2026 Aikido Pharma Inc reported a decrease in Revenue by -5.78% year on year, to $99 millions, compare to the 138% growth at Jun 30 2026.

Among companies within the Financial sector 5 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 31 to 44.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Investment Services Industry # 3
Financial Sector # 6
Overall # 44

Revenue TTM Y/Y Growth Statistics
High Average Low
691.09 %
295.91 %
-68.3 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 3
Sector # 16
S&P 500 # 146




Other Revenue Growth
Investment Services Industry Revenue Growth Trends and Statistics
Financial Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
DOMH's Revenue Growth Ratio versus Investment Services Industry, Financial Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decrease for the quarter ending Sep 30 2026 within Financial SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Tpg Inc -0.20%$ -0.197 millions
Financial Institutions Inc -0.40%$ -0.399 millions
Unitedhealth Group Incorporated-0.41%$ -0.413 millions
Travelers Companies inc -0.47%$ -0.465 millions
Diamondrock Hospitality Co-0.49%$ -0.491 millions
Eagle Bancorp Montana Inc -0.51%$ -0.506 millions
Choiceone Financial Services Inc -0.56%$ -0.564 millions
Lake Shore Bancorp Inc -0.60%$ -0.598 millions
W R Berkley Corp-0.78%$ -0.781 millions
Onity Group Inc -0.78%$ -0.785 millions
Blackstone Inc -0.83%$ -0.834 millions
Crawford and Co-0.87%$ -0.871 millions
Hg Holdings Inc -0.87%$ -0.874 millions
Udr Inc -0.88%$ -0.876 millions
Global Indemnity Group Llc-1.10%$ -1.104 millions
Lineage Inc -1.16%$ -1.162 millions
American Bitcoin Corp -1.35%$ -1.347 millions
Root Inc -1.68%$ -1.676 millions
Erie Indemnity Company-1.69%$ -1.689 millions
Mgic Investment Corp-1.78%$ -1.782 millions
Federal Home Loan Bank Of Chicago-1.81%$ -1.805 millions
Cedar Realty Trust Inc -1.84%$ -1.838 millions
First Busey Corporation-1.91%$ -1.912 millions
Loandepot Inc -2.19%$ -2.189 millions
Live Oak Bancshares Inc -2.35%$ -2.350 millions
Empire State Realty Op L p -2.37%$ -2.365 millions
Empire State Realty Trust Inc -2.37%$ -2.365 millions
Selective Insurance Group Inc-2.49%$ -2.486 millions
Qcr Holdings inc -2.49%$ -2.494 millions
Hsbc Usa Inc -2.51%$ -2.506 millions


About Aikido Pharma Inc Revenue Growth Rates (DOMH), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Dominari Holdings Inc (CIK 12239).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001437749-26-035967
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Dominari Holdings Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.